Literature DB >> 447856

Serum inhibitor of C5 fragment-mediated polymorphonuclear leukocyte chemotaxis associated with chronic hemodialysis.

S E Goldblum, D E Van Epps, W P Reed.   

Abstract

Abnormal granulocyte chemotaxis has been described in chronic hemodialysis patients. In this study, sera from 53 hemodialysis patients were tested for chemotactic inhibitory activity by a modified Boyden technique. Chemotactic inhibitory activity, defined as >20% inhibition of normal granulocyte chemotaxis, was found in 45% of patients. Only sera from patients having undergone >3 mo hemodialysis displayed chemotactic inhibitory activity and retained this inhibitory activity when retested 9 mo later. Four of five patients who had initially undergone <3 mo hemodialysis and lacked serum chemotactic inhibitory activity developed inhibitory activity when tested 9 mo later. Clinical evaluation of patients with serum chemotactic inhibitory activity showed that these patients did not have a significantly increased incidence of infection, although a trend toward decreased mortality during the time of study was observed (P = 0.0721). Serum chemotactic inhibitory activity was heat stable at 56 degrees C for 30 min and concentration dependent. The major inhibitory component was found to have a sedimentation coefficient of 4S by sucrose density gradient centrifugation. The chemotactic inhibitory activity was not precipitated by 30% ammonium sulfate, but was partially precipitated by 50% ammonium sulfate. Inhibitory sera effectively suppressed neutrophil migration in response to chemotactic C5 fragment and Escherichia coli derived chemotactic factor but was least effective in a system mediated by casein. Furthermore, normal neutrophils preincubated in hemodialysis patient sera displayed normal chemotactic responsiveness indicating a lack of cell-directed inhibition. Serum fractions that contained the inhibitor were found to directly act on the chemotactic C5 fragment, reducing its chemotactic activity. This study indicates that a circulating 4S, heat-stable, factor-directed inhibitor of granulocyte chemotaxis is present in the sera of many hemodialysis patients and probably results from the hemodialysis procedure.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 447856      PMCID: PMC372112          DOI: 10.1172/JCI109446

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  IMMUNOLOGIC STUDIES IN HUMAN ORGAN TRANSPLANTATION. 3. THE RELATIONSHIP OF DELAYED CUTANEOUS HYPERSENSITIVITY TO THE ONSET OF ATTEMPTED KIDNEY ALLOGRAFT REJECTION.

Authors:  W E WILSON; C H KIRKPATRICK; D W TALMAGE
Journal:  J Clin Invest       Date:  1964-10       Impact factor: 14.808

2.  The effect of severe battle injury and of post-traumatic renal failure on resistance to infection.

Authors:  H H BALCH
Journal:  Ann Surg       Date:  1955-08       Impact factor: 12.969

3.  Antibodies in schizophrenics.

Authors: 
Journal:  Br Med J       Date:  1967-09-02

4.  Adherence of blood components to dialyzer membranes: morphological studies.

Authors:  J W Marshall; D J Ahearn; R J Nothum; J Esterly; K D Nolph; J F Maher
Journal:  Nephron       Date:  1974       Impact factor: 2.847

5.  Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator.

Authors:  P A Ward; J L Berenberg
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

Review 6.  Renal failure and infection.

Authors:  J Z Montgomerie; G M Kalmanson; L B Guze
Journal:  Medicine (Baltimore)       Date:  1968-01       Impact factor: 1.889

7.  Phagocytosis by polymorphonuclear leukocytes in patients with renal failure on chronic hemodialysis.

Authors:  J C Guckian; L R Karrh; J L Copeland; J McCoy
Journal:  Tex Rep Biol Med       Date:  1971

8.  National registry of long-term dialysis patients.

Authors:  B T Burton; K K Krueger; F A Bryan
Journal:  JAMA       Date:  1971-11-01       Impact factor: 56.272

9.  Complement activity and inflammatory neutrophil exudation in man. Studies in patients with glomerulonephritis, essential hypocomplementemia and agammaglobulinemia.

Authors:  H Gewurz; A R Page; R J Pickering; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1967

10.  Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum.

Authors:  W M Newberry; J P Sanford
Journal:  J Clin Invest       Date:  1971-06       Impact factor: 14.808

View more
  7 in total

1.  IgA paraprotein inhibition of human neutrophil chemotaxis. Reduced activity following treatment with IgA-specific protease from Neisseria gonorrhoeae.

Authors:  D E Van Epps; A Plaut; G M Bernier; R C Williams
Journal:  Inflammation       Date:  1980-06       Impact factor: 4.092

2.  Alterations in activities of anaphylatoxin inactivator and chemotactic factor inactivator during hemodialysis.

Authors:  J R McCormick; D L Kreutzer; H J Keating; J Hupp; A Despins; M Moore
Journal:  Am J Pathol       Date:  1982-12       Impact factor: 4.307

3.  The immune status of uraemic children/adolescents with chronic renal failure and renal replacement therapy.

Authors:  R Drachman; M Schlesinger; H Shapira; A Drukker
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

4.  Gram-positive bacteria-induced granulocytopenia and pulmonary leukostasis in rabbits.

Authors:  S E Goldblum; W P Reed
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

5.  Reversal of hemodialysis granulocytopenia and pulmonary leukostasis: A clinical manifestation of selective down-regulation of granulocyte responses to C5adesarg.

Authors:  K M Skubitz; P R Craddock
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

6.  Lymphocyte subsets in hemodialysis patients treated with recombinant human erythropoietin.

Authors:  Y Ueki; M Nagata; S Miyake; Y Tominaga
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

7.  Bacillus anthracis-derived edema toxin (ET) counter-regulates movement of neutrophils and macromolecules through the endothelial paracellular pathway.

Authors:  Chinh Nguyen; Chiguang Feng; Min Zhan; Alan S Cross; Simeon E Goldblum
Journal:  BMC Microbiol       Date:  2012-01-09       Impact factor: 3.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.